As a consequence, high SEC62 expression levels were found to be associated with a higher incidence of lymphogenic and/or distant metastasis in HNSCC, NSCLC, melanoma, and breast cancer patients (Linxweiler et al., 2012; Bochen et al., 2017; Takacs et al., 2019; Müller et al., 2021). This evidence concerns the gene SEC62 and breast carcinoma.